残余肾功能与腹膜透析相关腹膜炎治疗结局的关系
单中心回顾性研究纳入181例患者共339次革兰阳性、革兰阴性及培养阴性腹膜透析相关腹膜炎发作,按尿肌酐清除率(0、>0-5、>5 ml/min)分组,用广义估计方程分析显示尿肌酐清除率>5 ml/min者治疗失败风险显著高于无尿患者,此关联见于革兰阳性及培养阴性腹膜炎。
要点
- 残余肾功能较高(尿肌酐清除率>5 ml/min)者革兰阳性或培养阴性腹膜炎治疗失败风险显著增高。
- 尿肌酐清除率>0-5 ml/min者治疗失败风险亦高于无尿患者。
- 革兰阴性腹膜炎中尿肌酐清除率与治疗失败无显著关联。
核心结论
- 以较高尿肌酐清除率衡量的残余肾功能与革兰阳性及培养阴性腹膜透析相关腹膜炎的治疗失败相关。
研究设计与样本
- 单中心研究纳入181例参与者,共339次革兰阳性、革兰阴性及培养阴性腹膜透析相关腹膜炎发作,时间范围为2003至2010年。
- 发作按参与者尿肌酐清除率分为0、>0-5和>5 ml/min三组,采用广义估计方程模型分析协变量调整后的关联。
主要发现
- 革兰阳性或培养阴性腹膜炎中,尿肌酐清除率>5 ml/min组治疗失败27/80次,无尿组20/119次,OR为6.80(95%CI 2.37至19.6)。
- 尿肌酐清除率>0-5 ml/min组治疗失败14/64次,较无尿组显著增高,OR为2.87(95%CI 1.12至7.35)。
- 尿肌酐清除率>5 ml/min组复发和再发性腹膜炎17/80次,无尿组12/119次,OR为6.76(95%CI 1.90至23.8)。
- 革兰阴性腹膜炎中,尿肌酐清除率与治疗失败及复发和再发性腹膜炎均无显著关联。
临床怎么用
- 对残余肾功能较好的腹膜透析相关腹膜炎患者(尤其革兰阳性或培养阴性者),应警惕治疗失败风险增高,加强监测。
局限性
- 研究为单中心回顾性设计,样本量有限,结论需外推验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Residual kidney function contributes to the clearance of antibiotics excreted by the kidneys, lowering the antibiotic concentration, which may adversely affect the treatment of peritoneal dialysis-associated peritonitis. The objective of our study was to examine the relationship between residual kidneyfunction and peritonitis treatment outcomes. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Our study included 181 participants who experienced 339 episodes of Gram-positive, Gram-negative, and culture-negative peritoneal dialysis-associated peritonitis at a single centerfrom 2003 to 2010. Episodes were categorized according to participants' urinary creatinine clearance (0, >0-5, and >5 ml/min). The data were analyzed using generalized estimating equation models to determine the covariate-adjusted association between urinary creatinine clearance and treatment failure (defined as relapse or recurrent peritonitis episodes, peritoneal catheter removal, or death from any cause during peritonitis treatment). RESULTS: Among episodes of peritonitis due to Gram-positive organisms or culture-negative infections, those experienced by participants with urinary creatinine clearance >5 ml/min had significantly higher odds of treatment failure than episodes experienced by anuric participants (27 of 80 versus 20 of 119 episodes resulting in treatment failure for creatinine clearance >5 versus 0 ml/min; odds ratio, 6.80; 95% confidence interval, 2.37 to 19.6). Episodes experienced by participants with creatinine clearance >0-5 ml/min also had significantly higher odds of treatment failure than episodes experienced by anuric participants (14 of 64 episodes resulting in treatment failure for creatinine clearance >0-5 ml/min; odds ratio, 2.87; 95% confidence interval, 1.12 to 7.35). The odds of relapse and recurrent peritonitis among participants with creatinine clearance >5 ml/min was also significantly higher compared with in anuric participants (17 of 80 versus 12 of 119 episodes resulting in relapse and recurrence for creatinine clearance >5 versus 0 ml/min; odds ratio, 6.76; 95% confidence interval, 1.90 to 23.8). Among participants with Gram-negative peritonitis, creatinine clearance was significantly associated with neither treatment failure nor relapse and recurrent peritonitis. CONCLUSIONS: Residual kidney function as measured by greater urinary creatinine clearance was associated with treatment failure among participants with Gram-positive and culture-negative peritonitis.
引用
- Whitty R, Bargman JM, Kiss A, et al. Residual Kidney Function and Peritoneal Dialysis-Associated Peritonitis Treatment Outcomes. Clin J Am Soc Nephrol. 2017. PMID: 29114005. doi:10.2215/CJN.00630117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。